Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep
| Autor: | Yue Hu, Li Jiang, Fang-cheng Cai, Chenggong Feng, Jin Chen |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Sleep Wake Disorders China Pediatrics medicine.medical_specialty Levetiracetam Adolescent Status epilepticus Anorexia Electroencephalography Behavioral Neuroscience Epilepsy Status Epilepticus Seizures medicine Humans Outpatient clinic Child Adverse effect medicine.diagnostic_test business.industry Infant medicine.disease Piracetam Treatment Outcome Neurology Child Preschool Anesthesia Etiology Anticonvulsants Female Neurology (clinical) medicine.symptom business medicine.drug |
| Zdroj: | Epilepsy & Behavior. 44:73-77 |
| ISSN: | 1525-5050 |
| DOI: | 10.1016/j.yebeh.2014.12.017 |
| Popis: | Purpose Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China. Methods Clinical data from all patients with ESES who received LEV therapy at our pediatric neurology outpatient clinic between 2007 and 2014 (n = 71) were retrospectively analyzed. The LEV dosage was 30–50 mg/kg/day. Electroencephalography recordings and neuropsychological evaluations were performed repeatedly for 3–75 months after the start of LEV therapy. Results Thirty-five (70%) of 50 patients who had seizures at the start of LEV therapy had a > 50% reduction in seizure frequency. Positive response on EEG was found during the first 3–4 months of LEV therapy in 32 (45%) of 71 patients, with normalization of EEG in 5 patients. Relapse occurred in 8 (25%) of the initial electrical responders. Hence, 47 patients (66%) still suffered from ESES and only 13 patients regained their baseline level of function at the last follow-up. The response to LEV was significantly associated with ESES duration, age at onset of ESES, and etiology of epilepsy. Although fatigue and anorexia were the primary adverse events, LEV was well-tolerated by all patients. Conclusions Levetiracetam is safe and may be efficient when used to treat ESES syndrome; however, the efficacy EEG neuropsychological outcomes is limited on the whole. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect